C4 Therapeutics Inc
CCCC
Health Care
2
exclusion reasons
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
C4 Therapeutics is a biotechnology company whose core research and development platform relies on the use of laboratory animals. The company’s primary therapeutic approach, targeted protein degradation, requires extensive preclinical testing in animal models to validate drug candidates before human trials. This fundamental reliance on animal testing for product development constitutes commercial exploitation of animals under the firm’s exclusion criteria.
The available evidence does not specify the scale or nature of the animal testing conducted by C4 Therapeutics. Public regulatory filings and legal documents focus on standard biopharmaceutical business risks, such as export controls and litigation, but do not provide detail on animal research protocols or volumes. The exclusion is based on the company’s operational model within the biotech sector, where animal testing is an inherent and material component of the drug discovery process for companies like C4 Therapeutics.
C4 Therapeutics is a clinical-stage biopharmaceutical company whose business model requires animal testing as a core component of its drug development process. The company’s SEC filings explicitly state that its preclinical studies include “nonclinical laboratory and animal tests” conducted in accordance with regulatory requirements to assess the safety and efficacy of its product candidates. These animal studies are a mandatory step prior to initiating human clinical trials.
The company’s own risk disclosures acknowledge that its product candidates have produced results in animal studies, but that the safety data from animals remains limited. Its research collaborations, such as a license agreement with Merck, also contain specific clauses governing animal research activities. As a biotechnology firm developing novel targeted protein degradation therapies, C4 Therapeutics’ operations are fundamentally reliant on animal testing to advance its pipeline, a practice that triggers exclusion under the animal testing policy.
Research Sources
5 organizations
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.